1 Linde K, Berner MM, Kriston L. St. John’s Wort for treating depression. Cochrane database of systematic reviews of meta analyses 2008.
2 Kasper S, Caraci F, Forti B, Drago S, Aguglia E. Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 2010;20:747–65.
3 Länger R. Die HMPC-Monographie zu Hypericum Hintergründe, Entstehung, Inhalte. Wien Med Wochenschr. 2010;160/21–22:557–563.
4 Kientsch U,Bürgi S,Ruedeberg C,Probst S, Honegger UE. St. John’s Wort extract Ze 117 (Hypericum perforatum) inhibits norepinephrine and serotonin uptake rinto rat brain slices and reduces β-adrenoceptor numbers on cultured rat brain cells. J Pharmacopsychiatry. 2001;34(1):56–60.
5 ButterweckV, Christoffel V, Nahrstedt A, et al. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sciences. 2003;73:627–39.
6 Hafner-Blumenstiel, V. Phytopharmaka als Ursache von unerwünschten Arzneimittelwirkungen. Therapeutische Umschau. 2011;68(1):54–7.
7 Borrelli F, Izzo, AA. Herb-drug interactions with St John’s Wort (Hypericum perforatum): An update on clinical observations. AAPS Journal. 2009;11(4):710–27.
8 Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St. John’s wort drug interactions. Eur J Clin Pharmacol. 2006;62(3):225–33.
9 Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H. The effect of St. John’s worth extracts on CYP3A: A systematic review of prospective clinical trials. Br J Clin Pharmacol. 2006;62:512–26.
10 Mueller SC, Majchen-Peszynska J, Uehleke B, et al. The extent of induction of CYP 3A by St. John’s wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol. 2006;62:29–36.
11 Mueller SC, Majchen-Peszynska J, Mundkowski RG, et al. No clinical relevant CYP 3A induction after St. John’s wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol. 2009;65(1):81–7.
Plus de références bibliographiques auprès des auteurs.